STAT

@statnews

Reporting from the frontiers of health & medicine. Sign up for any of our 10 free newsletters here: http://statnews.com/signup

Joined July 2015

5KFollowing

160KFollowers

Pinned

STAT@statnews · Jul 11

New event alert! Join STAT, Bill Gates, and a range of experts for a discussion on flattening barriers to improving women’s health — from research labs to clinics, from the most resource-poor regions to the wealthiest, and everywhere in between. Register: trib.al/4mPydLK

statnews's tweet card. Join Bill Gates and a range of experts for a discussion on flattening barriers to improving women’s health — from research labs to clini…

12.0K

STAT@statnews · 2 h

WASHINGTON — Members of a congressional oversight committee said Tuesday that they fear public trust in organ donation has been fractured after a federal report found that an organ procurement… trib.al/UMNQFmB

$statnews's tweet card. WASHINGTON — Members of a congressional oversight committee said Tuesday that they fear public trust in organ donation has been fractured after a federal$

2.0K

STAT@statnews · 3 h

New AI chatbot called Ash is different, Slingshot founders say, because its training model is based on real therapeutic conversations. trib.al/aZlaHDh

statnews's tweet card. New AI chatbot called Ash is different, Slingshot founders say, because its training model is based on real therapeutic conversations.

2.0K

STAT@statnews · 4 h

This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and medicine. trib.al/5vvKfrH

3.0K

STAT@statnews · 5 h

For people with diabetes, even a little activity every week is tied to better health trib.al/yavyyop

3.0K

STAT@statnews · 6 h

Sarepta Therapeutics faces an "arduous path” to try to get its gene therapy for Duchenne muscular dystrophy back onto the market, a senior FDA official told STAT. trib.al/FQ0RJhd

statnews's tweet card. Sarepta Therapeutics faces an "arduous path” to try to get its gene therapy for Duchenne muscular dystrophy back onto the market, a senior FDA official told STAT.

2.0K

STAT@statnews · 7 h

Slingshot AI, the a16z-backed mental health startup, launches a therapy chatbot. The company has raised $93 million for its chatbot Ash, which uses generative AI. trib.al/ZiMiG8u

2.0K

STAT@statnews · 8 h

The quick return of medical debt to credit reports is another blow to cancer patients. Americans should not be punished for having cancer. trib.al/EoUxaFN

statnews's tweet card. “Worsening a patient's credit can prevent them from getting a job, renting an apartment, or even paying their outstanding medical bills,” writes @llsusa’s chief medical officer.

2.0K

STAT@statnews · 9 h

Humana refiled a lawsuit Monday evening against the federal government, as the health insurance giant pushes to keep billions of dollars that could vanish as a result of downgraded ratings tied to its Medicare Advantage plans. trib.al/kxRoRb3

statnews's tweet card. Humana has refiled its lawsuit against the federal government over its Medicare Advantage ratings, with billions of dollars at stake.

2.0K

STAT Retweeted

Adam Feuerstein ✡️@adamfeuerstein · 10 h

EXCLUSIVE: Sarepta Therapeutics’ $SRPT Duchenne therapy faces ‘arduous’ path back to market, senior FDA official says statnews.com/2025/07/22/fda… via @Jasonmmast and me.

33.0K

STAT@statnews · 9 h

Exclusive: Sarepta Therapeutics, the maker of a gene therapy for Duchenne muscular dystrophy that is being temporarily shelved because of safety concerns, faces an “arduous and treacherous path” to try to get it back onto the market. trib.al/C2AC196

3.0K

STAT@statnews · 10 h

The FDA rejected a viral-based treatment from Replimune Group intended for patients with advanced skin cancer — a decision that again signals a hardened stance on drug approvals from Vinay Prasad. trib.al/HpPdRYJ

statnews's tweet card. The FDA on Tuesday rejected a skin therapy from Replimune Group, suggesting a hardened stance on drug approvals under new agency officials

2.0K

STAT@statnews · 11 h

In today's Morning Rounds newsletter: a failed long Covid drug may get another shot, the benefits of even a little activity for people with diabetes, and more. trib.al/g770tCE

2.0K

STAT@statnews · 12 h

A rare drug trial for long Covid failed, yielding lessons on study design - via @betsyladyzhets trib.al/V11pQ4t

statnews's tweet card. One of the few drug trials for a possible long Covid ended in disappointment. But lessons are leading to a second chance.

2.0K

STAT Retweeted

Elaine Chen@elaineywchen · 12 h

Latest: A race to develop a new class of narcolepsy drugs could not only transform treatment for patients with the rare sleep disorder, but also many people with common health conditions like Alzheimer's and depression who struggle to stay awake. statnews.com/2025/07/22/nar…

3.0K

STAT@statnews · 13 h

Takeda, Alkermes, and Centessa lead a race to develop orexin drugs that could transform narcolepsy treatment and tackle a range of other sleep issues. trib.al/er8CLiD

statnews's tweet card. A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with other conditions that cause them to struggle to stay awake.

2.0K

STAT Retweeted

Adam Feuerstein ✡️@adamfeuerstein · 16 h

Replimune $REPL skin cancer therapy rejected by FDA The decision is another signal that the FDA’s top regulator of cell and gene therapies is taking a hardened stance on new drug approvals statnews.com/2025/07/22/rep…

15.0K

STAT Retweeted

Isa Cueto@isabellacueto · 13 h

A recent analysis found the American Academy of Pediatrics, which in 2023 recommended new obesity medications for children, had undisclosed financial ties "at every level" to drugmakers. statnews.com/2025/07/22/stu…

2.0K

STAT@statnews · 13 h

Study of GLP-1 guidelines for teens points to potential for influence from drugmakers trib.al/kwWaS4S

statnews's tweet card. More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed financial ties to obesity drugmakers, a paper finds.

2.0K

STAT@statnews · 14 h

Sarepta Therapeutics reversed course and agreed to halt all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy trib.al/oJl8RKA

statnews's tweet card. Sarepta Therapeutics reversed course and agreed to halt all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy

2.0K

STAT@statnews · 14 h

In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy trib.al/VPwLMxv

statnews's tweet card. Sarepta Pharmaceuticals will halt all shipments of Elevidy, its gene therapy for Duchenne muscular dystrophy patients, by Tuesday evening.

2.0K